加载中
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
收盘时
US$12.56
+US$0.02 · +0.16%
盘后
US$12.56
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
日内区间
当前US$12.56
52周区间
当前US$12.56
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
39
偏贵
情绪
57
多空交织
风险
53
风险偏高
动量
30
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
日内区间
当前US$12.56
52周区间
当前US$12.56
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1695.9万 USD | 2022.2万 USD | 1868.6万 USD | 2649.6万 USD | 2376.3万 USD |
| 销货成本 | 1370.5万 USD | 1758.8万 USD | 1510.8万 USD | 1333.1万 USD | 1499.2万 USD |
| 毛利 | 325.4万 USD | 263.4万 USD | 357.8万 USD | 1316.5万 USD | 877.1万 USD |
| 研究与开发 | 1432万 USD | 887.8万 USD | 746.7万 USD | 1018.1万 USD | 1025.6万 USD |
| 销售、一般及管理费用 | 1392.5万 USD | 1291万 USD | 1137.7万 USD | 1037.1万 USD | 945.3万 USD |
| 营业费用 | 2853.3万 USD | 2201.6万 USD | 1907.9万 USD | 2082.6万 USD | 1999.2万 USD |
| 利息收入 | 185.9万 USD | 204.8万 USD | 234.1万 USD | 27万 USD | 1.1万 USD |
| 利息支出 | 66.3万 USD | 56.1万 USD | 33.5万 USD | 16.2万 USD | 16.7万 USD |
| 折旧和摊销 | 186万 USD | 148.3万 USD | 130.3万 USD | 127.2万 USD | 123.8万 USD |
| 营业利润 | −2527.9万 USD | −1938.2万 USD | −1550.1万 USD | −766.1万 USD | −1122.1万 USD |
| 净利润 | −2387.9万 USD | −3022.4万 USD | −671.6万 USD | −1959.9万 USD | −1355.1万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
